Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - Nasdaq Real Time Price. Currency in USD
1.9900+0.0500 (+2.58%)
At close: 04:00PM EDT
2.0600 +0.07 (+3.52%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9400
Open1.9500
Bid1.9800 x 1300
Ask2.0600 x 2200
Day's Range1.9350 - 2.0199
52 Week Range0.9400 - 2.2100
Volume1,111,192
Avg. Volume993,168
Market Cap100.825M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.2240
Earnings DateMay 15, 2023 - May 19, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treat

  • PR Newswire

    Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that it does not hold cash deposits or securities at either Silicon Valley Bank or Signature Bank, nor does it have any credit facility or other financial relationship with either institution. The Company maintain

  • Insider Monkey

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference is being recorded. I will now turn the conference over to your host, Monique Kosse of LifeSci Advisors, investor relations for Protalix. […]

Advertisement
Advertisement